Telaprevir (VX-950) Pegasys & Copegus in Hepatitis C

ID Number 07-0145

Principal Investigator(s)
Douglas Dieterich

Department(s) or Division(s)
Liver Diseases


In this study, VX06-950-107, patients will receive the study drug telaprevir in combination with peginterferon a-2a (Pegasys®) and ribavirin (Copegus®). The purpose of this study is to look at how a patient's body absorbs and processes these three drugs

Contact Information
Douglas Dieterich, MD

Recruiting Patients: No